adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy; 2. Treatment with any systemic anticancer therapy ≤ 3 weeks prior to cycle 1 day 1 3. Uncontrolled active infection (Hepatitis B and C infection are NOT exclusion criteria) and/or known HIV infection; 4. Renal failure requiring haemodialysis or peritoneal dialysis; 5. Patients who are pregnant or breast-feeding; 6. Patients with significantly diseased or obstructed gastrointestinal tract, malabsorption, uncontrolled vomiting or diarrhea resulting in inability to swallow oral medications; 7. Presence of symptomatic CNS metastasis 8. Unresolved toxicity from previous anti-cancer therapy or incomplete recovery from surgery, in particular oxaliplatin-induced peripheral neuropathy > grade 1. 
9. Any of the following within the 12 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis, or other thromboembolic event.       
    

NCT02384850_exc_T3
Procedure
systemic anticancer therapy
NCT02384850_exc_T4
Temporal
≤ 3 weeks prior to cycle 1
NCT02384850_exc_T5
Reference_point
cycle 1
NCT02384850_exc_T6
Condition
Hepatitis B infection
NCT02384850_exc_T7
Condition
Hepatitis C infection
NCT02384850_exc_T8
Negation
NOT
NCT02384850_exc_T9
Condition
infection
NCT02384850_exc_T10
Temporal
active
NCT02384850_exc_T11
Qualifier
Uncontrolled
NCT02384850_exc_T12
Scope
Hepatitis B and C infection are NOT exclusion criteria
NCT02384850_exc_T13
Condition
HIV infection
NCT02384850_exc_T14
Condition
Renal failure
NCT02384850_exc_T15
Procedure
haemodialysis
NCT02384850_exc_T16
Procedure
peritoneal dialysis
NCT02384850_exc_T17
Scope
haemodialysis or peritoneal dialysis
NCT02384850_exc_T18
Condition
pregnant
NCT02384850_exc_T19
Condition
breast-feeding
NCT02384850_exc_T22
Condition
obstructed gastrointestinal tract
NCT02384850_exc_T23
Condition
diseased gastrointestinal tract
NCT02384850_exc_T25
Qualifier
significantly
NCT02384850_exc_T28
Condition
malabsorption
NCT02384850_exc_T29
Condition
vomiting
NCT02384850_exc_T30
Qualifier
uncontrolled
NCT02384850_exc_T31
Condition
diarrhea
NCT02384850_exc_T32
Condition
inability to swallow oral medications
NCT02384850_exc_T34
Condition
CNS metastasis
NCT02384850_exc_T36
Qualifier
symptomatic
NCT02384850_exc_T37
Procedure
anti-cancer therapy
NCT02384850_exc_T38
Temporal
previous
NCT02384850_exc_T39
Procedure
surgery
NCT02384850_exc_T40
Condition
incomplete recovery
NCT02384850_exc_T41
Drug
oxaliplatin
NCT02384850_exc_T42
Qualifier
oxaliplatin-induced
NCT02384850_exc_T43
Condition
peripheral neuropathy
NCT02384850_exc_T44
Condition
Unresolved toxicity
NCT02384850_exc_T46
Temporal
within the 12 months prior to study drug administration
NCT02384850_exc_T47
Reference_point
study drug administration
NCT02384850_exc_T48
Condition
myocardial infarction
NCT02384850_exc_T49
Condition
unstable angina
NCT02384850_exc_T50
Condition
severe angina
NCT02384850_exc_T51
Condition
coronary artery bypass graft
NCT02384850_exc_T52
Condition
peripheral artery bypass graft
NCT02384850_exc_T53
Condition
symptomatic congestive heart failure
NCT02384850_exc_T54
Condition
cerebrovascular accident
NCT02384850_exc_T55
Condition
transient ischemic attack
NCT02384850_exc_T56
Condition
pulmonary embolism
NCT02384850_exc_T57
Condition
deep vein thrombosis
NCT02384850_exc_T58
Condition
other thromboembolic event
NCT02384850_exc_T59
Scope
myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis, or other thromboembolic event